Septerna (NASDAQ:SEPN) Shares Down 7.2% – Should You Sell?

Septerna, Inc. (NASDAQ:SEPN) was down 7.2% on Friday . The company traded as low as $13.20 and last traded at $13.19. Approximately 71,535 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 216,240 shares. The stock had previously closed at $14.21.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price for the company. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company.

Septerna Stock Performance

The company’s fifty day moving average price is $20.93.

Institutional Trading of Septerna

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Septerna during the 4th quarter worth approximately $3,197,000. Bank of New York Mellon Corp purchased a new position in Septerna during the fourth quarter worth $872,000. Lindbrook Capital LLC acquired a new position in shares of Septerna in the fourth quarter worth $481,000. Rhumbline Advisers purchased a new position in Septerna in the 4th quarter valued at about $458,000. Finally, M&T Bank Corp acquired a new position in shares of Septerna in the fourth quarter valued at approximately $376,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.